A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent upon Apoptosis

1. Download : Download high-res image (161KB)
2. Download : Download full-size image

     

Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine

A unique case of a 72-year-old man with chronic myelomonocytic leukemia (CMML) who developed hepatic veno-occlusive disease (VOD) after treatment with a single dose of vincristine and standard doses of cytarabine is described. Unexpected peroneal nerve palsy suggestive of vincristine neurotoxicity occurred concurrently and pointed to vincristine as the most likely cause of the VOD. To the best of our knowledge, association between vincristine and hepatic VOD has not been previously described in chemotherapy-naive patients with CMML.     

高速逆流色谱法分离纯化长春花中长春新碱

目的采用高速逆流色谱(HSCCC)分离纯化长春花中长春新碱,建立相关工艺条件,为工业生产提供参考数据。方法采用高速逆流色谱仪,氯仿-甲醇-0.3mol.L-1 HCl(4∶3∶2)溶剂体系,上相为固定相,下相为流动相,流动相流速为2.0mL.min-1,紫外检测波长为280nm,主机转速为800r.min-1,恒温循环温度为28℃。结果 HPLC检测HSCCC纯化后长春新碱质量分数为79.7%。结论高速逆流色谱纯化长春花中长春新碱容量大、分离纯度和效率高,避免了有机溶剂的大量使用,适用于工业生产高纯度产品。     

高效液相色谱法测定硫酸长春新碱的有关物质

目的 对硫酸长春新碱的有关物质检测方法进行方法学考察.方法 色谱柱为Shiseido C8柱(250 mm×4.6 mm,5μm);取二乙胺15mL加水985 mL,用磷酸调pH至7.5,作为流动相A,甲醇为流动相B,梯度洗脱;流速1.5 mL/min;检测波长297 nm;柱温30℃.结果 6份样品主峰和杂质峰峰面积的RSD分别为0.14%和0.24%;已知杂质硫酸长春碱质量浓度在0.510～51.04μg/mL范国内(相当于杂质水平0.05%~5.O%)与峰面积呈良好的线性关系(r=0.9999);平均加样回收率为100.10%.RSD为0.92%(n=6);有关物质(以硫酸长春碱计)检测限为0.05%.结论 该法专属性、重复性良好,方法准确,检测灵敏度高,耐用性好.可用于原料变更后的产品质量控制.     

顶空毛细管气相色谱法测定硫酸长春新碱中残留溶剂

目的 建立硫酸长春新碱中5种有机溶剂的分离测定方法.方法 采用顶空毛细管气相色谱法,FID检测器,应用DB-624毛细管柱对硫酸长春新碱中甲醇、乙醇、丙酮、苯、三氯甲烷进行测定.进样口温度:160℃;检测器温度:230℃;载气:N2;载气流速:10 mL/min;分流比:1:2;顶空进样器平衡温度:80℃;平衡时间:3...     

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B‐cell lymphomas. Despite unsatisfactory results with the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, it remains the reference front‐line therapy in these diseases, but has not been challenged in phase III trials. The Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang (GOELAMS) devised an alternative therapeutic schedule including etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine (VIP‐reinforced‐ABVD; VIP‐rABVD) and compared it to CHOP/21 as front‐line treatment in non‐cutaneous PTCL. All newly diagnosed patients were eligible. The primary objective was to improve the 2‐year event‐free survival (EFS) rate. Secondary objectives were to compare the response rate, overall survival, and toxicities as well as identify prognostic factors. Eighty‐eight patients were identified between 1996 and 2002 . Both arms were well balanced for patients’ characteristics in terms of histological and clinical presentation. No significant difference was observed between the two arms in terms of 2‐year EFS. Anaplastic large cell lymphoma type and Ann Arbor stage I–II were identified as two independent favourable prognostic factors influencing survival. VIP‐rABVD was not superior to CHOP/21 in terms of EFS as first‐line treatment of PTCL, confirming that CHOP/21 remains the reference regimen in these lymphomas.     

Bradykinin receptor antagonists and cyclooxygenase inhibitors in vincristine-and streptozotocin-induced hyperalgesia

Pain that accompanies neuropathy is difficult to treat. Analgesics administered as monotherapies possess low activities in relieving this kind of pain.The effect of the simultaneous administration of indomethacin (a preferential inhibitor of cyclooxygenase-1; COX-1) or celecoxib (a relatively selective inhibitor of cyclooxygenase-2; COX-2), with selective antagonists of bradykinin₂ (B₂) bradykinin1 (B₁) receptors (HOE 140 or des-Arg¹⁰-HOE 140) on the eleviation of diabetic and toxic neuropathic pain was investigated.Pretreatment with indomethacin (0.1 mg/kg, sc) increased the antihyperalgesic activity of low daily doses of HOE 140 or des-Arg¹⁰HOE 140 (70 nmol/kg, ip) in a diabetic (streptozotocin(STZ)-induced) neuropathy/hyperalgesia experimental model. Premedication with celecoxib before HOE 140 or des-Arg¹⁰HOE 140 administration resulted in a gradual reduction of STZ hyperalgesia. Furthermore, on days 23–24, almost complete abolishment of STZ hyperalgesia was observed. After cessation of drug administration, hyperalgesia quickly returned to the baseline threshold.The results of this study suggest that inhibitors of cyclooxygenases can increase the antihyperalgesic activity of selective antagonists of B₂ and B₁ receptors in diabetic and toxic neuropathic pain models. These observations may be clinically relevant.     

Magnesium ions and opioid agonists in vincristine-induced neuropathy

Neuropathic pain is difficult to treat. Classic analgesics (i.e., opioid receptor agonists) usually possess low activity. Therefore other agents such as antidepressants, anticonvulsants, and corticosteroids are used. It is commonly known that NMDA antagonists increase analgesic activity of opioids. Unfortunately, clinical use of NMDA antagonists is limited because of the relatively frequent occurrence of adverse effects e.g., memory impairment, psychomimetic effects, ataxia and motor in-coordination. Magnesium ions (Mg²⁺) are NMDA receptor blockers in physiological conditions. Therefore, in this study the effect of opioid receptor agonists and the influence of Mg²⁺ on the action of opioid agonists in vincristine-induced hyperalgesia were examined. Opioid agonists such as morphine (5 mg/kg, ip), and fentanyl (0.0625 mg/kg, ip), as well as the partial agonist buprenorphine (0.075 mg/kg, ip) administered alone on 5 consecutives days did not modify the hyperalgesia in vincristine rats. In contrast, pretreatment with a low dose of magnesium sulfate (30 mg/kg, ip) resulted in a progressive increase of the analgesic action of all three investigated opioids. After discontinuation of drug administration, the effect persisted for several days.